Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
Authors:
Open Access
- 20 October 2023
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (11) , 1363-1374
Abstract
Purpose of Review: [177Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [177Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination treatments. Recent Findings: A variety of agents to combine with [177Lu]Lu-PSMA-617 are currently under investigation including alpha radiation-emitting pharmaceuticals, radiosensitizers, taxane chemotherapeutics, androgen receptor pathway inhibitors, immune checkpoint inhibitors, and external beam radiation. Actinium-225 (225Ac)-labeled PSMA-targeting inhibitors are the most studied pharmaceuticals for combination therapy or as an alternative for treatment after progression under [177Lu]Lu-PSMA-617 therapy. Summary: Alpha emitters seem to have a potential of achieving a response to PSMA-targeting radionuclide therapy in both initial non-responders or responders to [177Lu]Lu-PSMA-617 later developing treatment resistance. Emerging evidence for immunostimulatory effects of radiopharmaceuticals and first prospective studies support the combination of [177Lu]Lu-PSMA-617 and immune checkpoint inhibition for late-stage prostate cancer.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BA 6696/2-1)
- Deutsches Krebsforschungszentrum (DKFZ)
This publication has 51 references indexed in Scilit:
- Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate CancerClinical Nuclear Medicine, 2017
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted RadiotherapyPLOS ONE, 2014
- Mammalian Base Excision Repair: the Forgotten ArchangelNucleic Acids Research, 2013
- Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell linesJournal of Biosciences, 2012
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- A Tissue-Specific Enhancer of the Prostate-Specific Membrane Antigen Gene, FOLH1Genomics, 2001
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression.1995